 Home > Active Ingredient News > Drugs Articles > Research tools for anticancer drug targets

Research tools for anticancer drug targets

 Last Update: 2022-03-07
 Source: Internet
 Author: User

Tags

1 8 pipe

twist products

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Cancer has always been a global health problem

Note: The graph on the left shows the estimated number of new cancer cases in 2020

The graph on the right shows the estimated number of cancer deaths in 2020

Data source: GLOBCAN 2020

Graphic source: Global Cancer Observatory

Currently, patients have a variety of treatment options, including chemotherapy, targeted therapy, and immunotherapy

Targeted therapy: Use is a precision medicine that targets proteins that control the growth, division and spread of cancer cells

Immunotherapy: Harnesses the ability of a patient's own immune system to fight cancer

Table 1: FDA-approved treatments for PD-1 and PD-L1

In addition to this, researchers are currently actively investigating new targets, including T-cell immune receptors (TIGITs) with Ig and EM domains

In January 2021, based on data from the Phase II CITYSCAPE trial, Roche announced that the combination of tiragolumab (an anti-TIGIT antibody) and atezolizumab showed encouraging efficacy and safety in PD-L1-positive metastatic non-small cell lung cancer sex

At present, both small molecule targeted therapy and immunotherapy alone have shown good clinical effects

01 Recombinant drug target protein

Note: The graph on the left shows the estimated global cancer deaths in 2020

The graph on the right shows the estimated 2020 cancer deaths in women

Data source: GLOBCAN 2020

Graphic source: Global Cancer Observatory

According to statistics, lung cancer is the leading cause of cancer death in both men and women worldwide, with an estimated 1.

Legend: Products containing the extracellular or intracellular domains of proteins

(A) Binding assay of EGF and EGFR: immobilized human EGF hFc (Cat: 10605-H01H) at a concentration of 2 µg/ml can bind to human EGFR His (Cat: 10001-H08H)

(B) Determination of specific activity of EGFR (AA668-1210)

In addition, in order to protect themselves, tumor cells can also evade detection by the patient's immune system by staying away from immune cells

At present, therapeutic antibodies that block PD-1 and its ligand PD-L1 have been proved to have clinical efficacy by scientific research, and anti-CD47 antibodies can also enhance the phagocytosis of tumor cells by the patient's body by blocking the binding of CD47 to SIRPa role

02 Cytokines

Functional analysis of partial antibodies may also require testing on cells, in which case cytokines are often used

Reference source:

4.
Lei Zhong et al.
, “Small Molecules in Targeted Cancer Therapy: Advances, Challenges, and Future Perspectives,” SignalTransduction and Targeted Therapy 6, no.
1 (2021): 1–48, https://doi.
org/ 10.
1038/s41392-021-00572-w.

5.
“Herceptin (Trastuzumab) FDA Approval History,” Drugs.
com, accessed January 10, 2022, https:// “Herceptin (Trastuzumab) FDA Approval History,” Drugs.
com, accessed January 10, 2022, https:// 6.
“Iressa (Gefitinib) FDA Approval History - Drugs.
Com,” accessed January 10, 2022, https:// “Iressa (Gefitinib) FDA Approval History - Drugs.
Com,” accessed January 10, 2022, https:// 7.
Raju K.
Vaddepally et al.
, “Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence,” Cancers 12, no.
3 (March 20, 2020), https://doi.
org /10.
3390/cancers12030738.

7.
Raju K.
Vaddepally et al.
, “Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence,” Cancers 12, no.
3 (March 20, 2020), https://doi.
org /10.
3390/cancers12030738.

8.
P.
Zatloukalová et al.
, “[The Role of PD-1/PD-L1 Signaling Pathway in Antitumor Immune Response],” Klinicka Onkologie: CasopisCeske a Slovenske Onkologicke Spolecnosti 29 Suppl 4, no.
Suppl 4 (Fall 2016) : 72–77.

9.
Hyun Tae Lee et al.
, “Molecular Mechanism of PD-1/PD-L1 Blockade via Anti-PD-L1 Antibodies Atezolizumab and Durvalumab,” Scientific Reports 7 (July 17, 2017), https://doi.
org /10.
1038/s41598-017-06002-8.

10.
Hyun Tae Lee, Sang Hyung Lee, and Yong-Seok Heo, “Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology,” Molecules 24, no.
6 (March 26, 2019), https://doi.
org/10.
3390/molecules24061190.

11.
Francesco Passiglia et al.
, “

Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?

,” ImmunoTargets and Therapy 10 (February 5, 2021): 9–26, https://doi.
org/10.
2147/ITT.
S253581.

12.
“Genentech's Novel Anti-TIGIT Tiragolumab Granted FDA Breakthrough Therapy Designation in Combination With Tecentriq for PD-L1-High Non-Small Cell Lung Cancer,” January 5, 2021, https:// /20210104005887/en/Genentech%E2%80%99s-Novel-Anti-TIGIT-Tiragolumab-GrantedFDA-Breakthrough-Therapy-Designation-in-Combination-With-Tecentriq-for-PD-L1-High-Non-Small-Cell -Lung-Cancer

13.
Johann S.
Bergholz et al.
, “Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications,” Clinical Cancer Research 26, no.
21 (November 1, 2020): 5557–66, https:// doi.
org/10.
1158/1078-0432.
CCR-19-2300.

14.
Deric L.
Wheeler, Emily F.
Dunn, and Paul M.
Harari, “Understanding Resistance to EGFR Inhibitors—Impact on Future Treatment

Strategies,” Nature Reviews.
Clinical Oncology 7, no.
9 (September 2010): 493–507, https://doi.
org/10.
1038/nrclinonc.
2010.
97.

15.
Remah Ali and Michael K.
Wendt, “The Paradoxical Functions of EGFR during Breast Cancer Progression,” Signal Transduction

and Targeted Therapy 2, no.
1 (2017): 1–7, https://doi.
org/10.
1038/sigtrans.
2016.
42.

16.
“Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in

Non-Small-Cell Lung Carcinoma Treatments,” PLOS ONE 10, no.
5 (May 20, 2015): e0128360,

https://doi.
org/10.
1371/journal.
pone.
0128360.

17.
H.
Harjunpää and C.
Guillerey, “TIGIT as an Emerging Immune Checkpoint,” Clinical & Experimental Immunology 200, no.
2

(2020): 108–19, https://doi.
org/10.
1111/cei.
13407.

18.
Wenting Zhang et al.
, “Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis,” Frontiers in Immunology 11 (2020),

https://doi.
org/10.
3389/fimmu.
2020.
00018.

19.
Zatloukalová et al.
, “[The Role of PD-1/PD-L1 Signaling Pathway in Antitumor Immune Response].
”

20.
Theresa L.
Whiteside and Ronald B.
Heberman, “Antitumor Effector Cells in Humans,” Holland-Frei Cancer Medicine.
6th Edition,

2003, https:// https:// 21.
“TIGIT - an Overview | ScienceDirect Topics,” accessed March 29, 2021,

21.
“TIGIT - an Overview | ScienceDirect Topics,” accessed March 29, 2021,

https:// 22.
Fanqiao Meng et al.
, “Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic

22.
Fanqiao Meng et al.
, “Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic

Syndromes,” Frontiers in Oncology 10 (2020), https://doi.
org/10.
3389/fonc.
2020.
01595.

23.
Xiaowan Yin et al.
, “Expression of the Inhibitory Receptor TIGIT Is Up-Regulated Specifically on NK Cells With CD226 Activating

Receptor From HIV-Infected Individuals,” Frontiers in Immunology 9 (2018), https://doi.
org/10.
3389/fimmu.
2018.
02341

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.